J01GB01 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
299	Cystic fibrosis	2

299. Cystic fibrosis

---

Clinical trials : 1,696 /  Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2012-004437-16-NL (EUCTR)	15/05/2013	19/03/2013	Pharmacokinetic evaluation and local tolerability of dry powder tobramycin by a novel device in patients with non cystic fibrosis bronchiectasis	Pharmacokinetic evaluation and tolerability of dry powder tobramycin by a novel device in patients with non cystic fibrosis bronchiectasis - Tobra-02	BronchiectasisLung infections;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Product Name: Dry powder tobramycin Product Code: J01GB01 INN or Proposed INN: Tobramycin dry powder Other descriptive name: TOBRAMYCIN	University Medical Center Groningen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Netherlands
2	EUCTR2016-005014-21-NL (EUCTR)		31/10/2020	Pharmacokinetic evaluation and tolerability of dry powder tobramycin viathe Cyclops® in children with cystic fibrosis	Pharmacokinetic evaluation and tolerability of dry powder tobramycin via the Cyclops® in children with cystic fibrosis - DPI-tobra-child	Cystic FibrosisLung infections;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Product Name: Dry powder tobramycin Product Code: J01GB01 INN or Proposed INN: TOBRAMYCIN Other descriptive name: TOBRAMYCIN Product Name: Nebulization tobramycin INN or Proposed INN: TOBRAMYCIN Other descriptive name: TOBRAMYCIN	University Medical Center Groningen	NULL	NA			Female: yes Male: yes	10	Phase 2	Netherlands